Folgen
Andrea Antinori
Andrea Antinori
Director HIV/AIDS Unit - INMI - National Institute for Infectious Diseases L. Spallanzani, Roma
Bestätigte E-Mail-Adresse bei inmi.it
Titel
Zitiert von
Zitiert von
Jahr
Updated research nosology for HIV-associated neurocognitive disorders
A Antinori, G Arendt, JT Becker, BJ Brew, DA Byrd, M Cherner, DB Clifford, ...
Neurology 69 (18), 1789-1799, 2007
30132007
Combination antiretroviral therapy and the risk of myocardial infarction
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
New England Journal of Medicine 349 (21), 1993-2003, 2003
21002003
Monkeypox virus infection in humans across 16 countries—April–June 2022
JP Thornhill, S Barkati, S Walmsley, J Rockstroh, A Antinori, LB Harrison, ...
New England Journal of Medicine 387 (8), 679-691, 2022
15052022
Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study
Data Collection on Adverse Events of Anti-HIV Drugs Study Group
Archives of internal medicine 166 (15), 1632-1641, 2006
14702006
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration
D: A: D Study Group
The Lancet 371 (9622), 1417-1426, 2008
11452008
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of …
AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, O Degen, ...
The Lancet 393 (10189), 2428-2438, 2019
9932019
Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients
AA Monforte, AC Lepri, G Rezza, P Pezzotti, A Antinori, AN Phillips, ...
Aids 14 (5), 499-507, 2000
7602000
Mapping the human genetic architecture of COVID-19
Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ...
Nature 600 (7889), 472-477, 2021
6802021
Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection
A Ammassari, R Murri, P Pezzotti, MP Trotta, L Ravasio, P De Longis, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 28 (5), 445-449, 2001
6732001
Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature.
Ammassari
6682002
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b …
B Clotet, J Feinberg, J van Lunzen, MA Khuong-Josses, A Antinori, ...
The Lancet 383 (9936), 2222-2231, 2014
6132014
Late presentation of HIV infection: a consensus definition
A Antinori, T Coenen, D Costagiola, N Dedes, M Ellefson, J Gatell, ...
HIV medicine 12 (1), 61-64, 2011
5962011
Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022
A Antinori, V Mazzotta, S Vita, F Carletti, D Tacconi, LE Lapini, ...
Eurosurveillance 27 (22), 2200421, 2022
5052022
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …
L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ...
The Lancet infectious diseases 11 (5), 363-371, 2011
4612011
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study
N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ...
European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010
4362010
Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors
V Tozzi, P Balestra, R Bellagamba, A Corpolongo, MF Salvatori, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 45 (2), 174-182, 2007
4122007
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 …
P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ...
The Lancet 393 (10167), 143-155, 2019
3862019
Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons
A Ammassari, A Antinori, MS Aloisi, MP Trotta, R Murri, L Bartoli, ...
Psychosomatics 45 (5), 394-402, 2004
3842004
Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy
F Starace, A Ammassari, MP Trotta, R Murri, P De Longis, C Izzo, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 31, S136-S139, 2002
3662002
Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects
A De Luca, R Bugarini, AC Lepri, M Puoti, E Girardi, A Antinori, A Poggio, ...
Archives of internal medicine 162 (18), 2125-2132, 2002
3182002
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20